An emerging treatment for clinical depression has reached an important milestone. This week, the Food and Drug Administration ...
The U.S. Food and Drug Administration expanded approval for Johnson & Johnson’s nasal spray, Spravato, to allow it to be used ...
The announcement was welcome news for those with major depressive disorder, affecting an estimated 8.3% of the adult ...
The US Food and Drug Administration has approved a new nasal spray for depression treatment. Known as Spravato and ...
The FDA says esketamine, an antidepressant derived from the anesthetic and party drug ketamine, can now be prescribed on its ...
In 2019, the U.S. Food and Drug Administration (FDA) approved the use of a nasal spray ketamine derivative called esketamine (Spravato) to treat depression in adults, according to the National ...
SINGAPORE – Ketamine, the controlled drug best known ... first authorized sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy on their patients ...
Esketamine, the ketamine-derived nasal spray sold under the brand name Spravato (esketamine), is indicated for patients with treatment-resistant depression. In October 2023, the FDA warned about ...
SINGAPORE (The Straits Times/ANN): Ketamine, the controlled drug best ... first authorised sale of an esketamine nasal spray for serious depression – five psychiatrists who used the therapy ...
Moreover, at one and two weeks post-infusion, ketamine failed to beat either the saline or the active placebos. Why was the FDA approval of esketamine so controversial among many researchers?
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback